![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GRAMD3 |
Gene summary for GRAMD3 |
![]() |
Gene information | Species | Human | Gene symbol | GRAMD3 | Gene ID | 65983 |
Gene name | GRAM domain containing 2B | |
Gene Alias | GRAMD3 | |
Cytomap | 5q23.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q96HH9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
65983 | GRAMD3 | LN46 | Human | Oral cavity | OSCC | 7.97e-13 | 6.45e-01 | 0.1666 |
65983 | GRAMD3 | SYSMH3 | Human | Oral cavity | OSCC | 2.19e-04 | 1.89e-01 | 0.2442 |
65983 | GRAMD3 | SYSMH6 | Human | Oral cavity | OSCC | 1.17e-12 | 2.96e-01 | 0.1275 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GRAMD3 | SNV | Missense_Mutation | novel | c.1057N>G | p.Gln353Glu | p.Q353E | Q96HH9 | protein_coding | tolerated(0.38) | benign(0.006) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
GRAMD3 | SNV | Missense_Mutation | novel | c.1102G>C | p.Val368Leu | p.V368L | Q96HH9 | protein_coding | tolerated(1) | benign(0.003) | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
GRAMD3 | insertion | Frame_Shift_Ins | novel | c.177_178insTGCCATCTTAACATGTCTTTCTTTAGGCTCAGTCTCCATGGAGT | p.Pro60CysfsTer49 | p.P60Cfs*49 | Q96HH9 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
GRAMD3 | SNV | Missense_Mutation | c.331N>A | p.Glu111Lys | p.E111K | Q96HH9 | protein_coding | deleterious(0) | benign(0.09) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
GRAMD3 | insertion | Frame_Shift_Ins | novel | c.1003_1004insT | p.Val337CysfsTer13 | p.V337Cfs*13 | Q96HH9 | protein_coding | TCGA-Q1-A73Q-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
GRAMD3 | SNV | Missense_Mutation | novel | c.530N>C | p.Lys177Thr | p.K177T | Q96HH9 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GRAMD3 | SNV | Missense_Mutation | c.1333A>G | p.Asn445Asp | p.N445D | Q96HH9 | protein_coding | tolerated(0.74) | benign(0.001) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GRAMD3 | SNV | Missense_Mutation | c.1305N>G | p.Ile435Met | p.I435M | Q96HH9 | protein_coding | deleterious(0) | possibly_damaging(0.621) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
GRAMD3 | SNV | Missense_Mutation | c.1004T>G | p.Leu335Arg | p.L335R | Q96HH9 | protein_coding | tolerated(0.21) | benign(0.368) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
GRAMD3 | SNV | Missense_Mutation | rs780081964 | c.592N>T | p.Pro198Ser | p.P198S | Q96HH9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |